Zvezdan Pirtošek comments on the debate he moderated at CONy 2024 over whether or not lecanemab should be extended beyond 18 months.
Zvezdan Pirtošek comments on the debate he moderated at CONy 2024 over whether or not lecanemab should be extended beyond 18 months.